c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function
Open accessAbstract
Accumulating evidence indicates that interactions between the epidermal growth factor receptor (EGFR) and the nonreceptor tyrosine kinase c-Src may contribute to an aggressive phenotype in multiple human tumors. Previous work from our laboratory demonstrated that murine fibroblasts which overexpress both these tyrosine kinases display synergistic increases in DNA synthesis, soft agar growth, and tumor formation in nude mice, and increased phosphorylation of the receptor substrates Shc and phospholipase gamma as compared with single overexpressors. These parameters correlated with the ability of c-Src and EGFR to form an EGF-dependent heterocomplex in vivo. Here we provide evidence that association between c-Src and EGFR can occur directly, as shown by receptor overlay experiments, and that it results in the appearance of two novel tyrosine phosphorylations on the receptor that are seen both in vitro and in vivo following EGF stimulation. Edman degradation analyses and co-migration of synthetic peptides with EGFR-derived tryptic phosphopeptides identify these sites as Tyr845 and Tyr1101. Tyr1101 lies within the carboxyl-terminal region of the EGFR among sites of receptor autophosphorylation, while Tyr845 resides in the catalytic domain, in a position analogous to Tyr416 of c-Src. Phosphorylation of Tyr416 and homologous residues in other tyrosine kinase receptors has been shown to be required for or to increase catalytic activity, suggesting that c-Src can influence EGFR activity by mediating phosphorylation of Tyr845. Indeed, EGF-induced phosphorylation of Tyr845 was increased in MDA468 human breast cancer cells engineered to overexpress c-Src as compared with parental MDA 468 cells. Furthermore, transient expression of a Y845F variant EGFR in murine fibroblasts resulted in an ablation of EGF-induced DNA synthesis to nonstimulated levels. Together, these data support the hypothesis that c-Src-mediated phosphorylation of EGFR Tyr845 is involved in regulation of receptor function, as well as in tumor progression.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Src family kinases are necessary for full activation of EGFR.
“it is well established that Src, or Src family kinases (SFKs), are necessary for full activation of the EGFR (Biscardi et al., 1999a).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Biscardi et al., 1999a
Cites
Ellis, L., Clauser, E., Morgan, D. O., Edery, M., Roth, R. A., & Rutter, W. J. (1986) · Cell · doi:10.1016/0092-8674(86)90786-5 · Cited by 1,070 · see citing works
Autophosphorylation sites on the epidermal growth factor receptor
Downward, J., Parker, P., & Waterfield, M. D. (1984) · Nature · doi:10.1038/311483a0 · Cited by 704 · see citing works
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · see citing works
Maa, M. C., Leu, T. H., McCarley, D. J., Schatzman, R. C., & Parsons, S. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6981 · Cited by 330 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Epidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565 · see citing works
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · see citing works
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515 · see citing works
Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310 · see citing works
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170 · see citing works
Ségaliny, A. I., Tellez-Gabriel, M., Heymann, M.-F., & Heymann, D. (2015) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.01.001 · Cited by 164 · see citing works
Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157 · see citing works
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139 · see citing works
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133 · see citing works
“…several cellular responses including cell proliferation, survival, angiogenesis, migration, and metastasis (reviewed in (Abram and Courtneidge, 2000; Biscardi et al., 1999b; Blume-Jensen and Hunter, 2001; Marmor et al., 2004; Prenzel et al., 2001; Schlessinger, 2000; Yarden and Sliwkowski, 2001)).”
BackgroundWang, X.-Q., Sun, P., & Paller, A. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308818200 · Cited by 87 · see citing works
Gao, M., Zhan, Y.-Q., Yu, M., Ge, C.-H., Li, C.-Y., Zhang, J.-H., Wang, X.-H., Ge, Z.-Q., & Yang, X.-M. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.013 · Cited by 52 · see citing works
The molecular rationale of Src inhibition in colorectal carcinomas
Gargalionis, A. N., Karamouzis, M. V., & Papavassiliou, A. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28299 · Cited by 47 · see citing works
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26 · see citing works
Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i> -mutated Non–small Cell Lung Cancers
Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0482 · Cited by 14 · see citing works
SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities
Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7 · see citing works
- Authors
- Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J.
- Affiliations
- University of Virginia Health System (US)
- Corresponding author
- Parsons, Sarah J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-03
- Volume
- 274
- Issue
- 12
- Pages
- 8335-8343
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022847745
- Cited by
- 649
- References
- 4
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 9 · 2023: 16 · 2022: 11 · 2021: 16 · 2020: 10 · 2019: 17 · 2018: 10 · 2017: 24 · 2016: 18 · 2015: 29 · 2014: 31 · 2013: 36 · 2012: 36
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA071449, CA3948, CA 71449)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Keywords
- Src kinase, epidermal growth factor receptor, receptor tyrosine phosphorylation, non-receptor tyrosine kinase, EGF signaling, receptor autophosphorylation, breast cancer cells, tumor progression, kinase activity
- MeSH terms
- CSK Tyrosine-Protein Kinase, Amino Acid Sequence, Animals, Cell Line, Humans, Mice, Inbred C3H, Mitosis, Molecular Sequence Data, Peptide Mapping, Phosphorylation, Protein Binding, Protein-Tyrosine Kinases, Structure-Activity Relationship, Tumor Cells, Cultured, Tyrosine, src Homology Domains, src-Family Kinases, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
